Vivos Therapeutics (NASDAQ:VVOS) Chairman & CEO Kirk Huntsman joins Natalie Stoberman from the Proactive studios to discuss the company's Q1 financial and operational highlights.
Huntsman says the main highlight of Q1 comes from acquisition of certain U.S. and international patents, product rights, and other miscellaneous intellectual property from Advanced Facialdontics to fill gaps for Vivos' product line. Huntsman also shares how the company's cost reduction efforts, distribution agreements, and the potential for further growth have been executed while the company continues to reach more patients and providers.